Esperion Therapeutics plans to acquire Corstasis Therapeutics. The goal is to expand the cardiovascular franchise. The acquisition adds Enbumyst to the portfolio. Enbumyst is a nasal spray containing bumetanide. Bumetanide is a diuretic used in cardiovascular therapy. This step will strengthen Esperion's offer in the area of cardiovascular diseases.